Demonstration of substantial benefits from SGLT2 inhibitors in reducing kidney disease progression and mortality in patients with CKD has reopened the question of whether screening for CKD is effective and provides good value.2,3 In our previous cost-effectiveness analysis,8 we found that screening is cost-effective overall for US adults aged 35 years and older, but we did not evaluate when to begin screening different age cohorts, which requires comparison of immediate treatment against strategies that defer screening to older ages. This evidence concerns the gene SLC5A2 and chronic kidney disease.